Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks has identified LeMaitre Vascular (LMAT) as a strong growth stock, assigning it a Growth Score of B and a Zacks Rank #2. This assessment is driven by a projected 17.2% EPS growth this year, significantly outpacing the industry's 13% average, and robust year-over-year cash flow growth of 35.1% compared to the industry's 1.2%. Additionally, positive earnings estimate revisions, with the Zacks Consensus Estimate for the current year surging 5.6% over the past month, collectively position LMAT for potential outperformance.

Analysis

LeMaitre Vascular (LMAT) exhibits a strong growth profile, supported by a Zacks Rank #2 (Buy) and a Growth Score of B. The company's forward-looking prospects appear favorable, with projected EPS growth for the current year at 17.2%, which significantly outpaces the medical device industry's average forecast of 13%. This earnings momentum is complemented by exceptionally robust cash flow generation; LMAT's year-over-year cash flow growth stands at 35.1%, starkly contrasting with the 1.2% industry average. This financial strength is not a recent anomaly, as evidenced by a sustained 18.1% annualized cash flow growth rate over the past 3-5 years, more than double the industry's 8% average. Furthermore, positive sentiment from analysts is a key catalyst, demonstrated by a 5.6% upward revision in the Zacks Consensus Estimate for current-year earnings over the last month. The combination of accelerating earnings, superior cash flow enabling self-funded expansion, and rising analyst estimates positions LMAT as a standout performer in its sector.

Key Decisions for Investors

• Given the combination of strong projected EPS growth, superior cash flow generation, and positive earnings estimate revisions, investors with a growth-focused strategy should consider LMAT for potential outperformance.
• Monitor upcoming earnings releases closely to validate that the company is on track to meet its projected 17.2% EPS growth and maintain its significant cash flow advantage over the industry.
• Investors should be aware that the article identifies growth stocks as carrying above-average risk and volatility, and therefore should manage position sizing in LMAT accordingly.
• Continue to benchmark LMAT's fundamental metrics against industry averages, as its current premium valuation is justified by its significant outperformance in growth and cash flow.